JP2022516974A5 - - Google Patents

Info

Publication number
JP2022516974A5
JP2022516974A5 JP2021539935A JP2021539935A JP2022516974A5 JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
composition according
active agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516974A (ja
JP7467479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012647 external-priority patent/WO2020146440A1/en
Publication of JP2022516974A publication Critical patent/JP2022516974A/ja
Publication of JP2022516974A5 publication Critical patent/JP2022516974A5/ja
Priority to JP2024059887A priority Critical patent/JP2024081769A/ja
Application granted granted Critical
Publication of JP7467479B2 publication Critical patent/JP7467479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539935A 2019-01-09 2020-01-08 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法 Active JP7467479B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024059887A JP2024081769A (ja) 2019-01-09 2024-04-03 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962790326P 2019-01-09 2019-01-09
US62/790,326 2019-01-09
PCT/US2020/012647 WO2020146440A1 (en) 2019-01-09 2020-01-08 Antiproliferative compounds and second active agents for use in treating multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024059887A Division JP2024081769A (ja) 2019-01-09 2024-04-03 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法

Publications (3)

Publication Number Publication Date
JP2022516974A JP2022516974A (ja) 2022-03-03
JP2022516974A5 true JP2022516974A5 (cg-RX-API-DMAC7.html) 2023-01-24
JP7467479B2 JP7467479B2 (ja) 2024-04-15

Family

ID=69500830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539935A Active JP7467479B2 (ja) 2019-01-09 2020-01-08 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法
JP2024059887A Pending JP2024081769A (ja) 2019-01-09 2024-04-03 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024059887A Pending JP2024081769A (ja) 2019-01-09 2024-04-03 多発性骨髄腫の治療における抗増殖化合物及び第2の活性薬剤とそれらの併用方法

Country Status (23)

Country Link
US (3) US11660297B2 (cg-RX-API-DMAC7.html)
EP (2) EP3908281B9 (cg-RX-API-DMAC7.html)
JP (2) JP7467479B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210126011A (cg-RX-API-DMAC7.html)
CN (3) CN118178417A (cg-RX-API-DMAC7.html)
AU (1) AU2020205643C1 (cg-RX-API-DMAC7.html)
CA (1) CA3125753A1 (cg-RX-API-DMAC7.html)
DK (1) DK3908281T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191903A1 (cg-RX-API-DMAC7.html)
ES (1) ES2995189T3 (cg-RX-API-DMAC7.html)
FI (1) FI3908281T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241309T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068895T2 (cg-RX-API-DMAC7.html)
IL (1) IL284671B2 (cg-RX-API-DMAC7.html)
LT (1) LT3908281T (cg-RX-API-DMAC7.html)
MX (2) MX2021008294A (cg-RX-API-DMAC7.html)
PL (1) PL3908281T3 (cg-RX-API-DMAC7.html)
PT (1) PT3908281T (cg-RX-API-DMAC7.html)
RS (1) RS66066B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202107413YA (cg-RX-API-DMAC7.html)
SI (1) SI3908281T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400388T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020146440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010556A (es) * 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
AU2020206692B2 (en) 2019-01-09 2025-03-27 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
DK3908281T3 (da) * 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
EP4297750A1 (en) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
KR20240013793A (ko) * 2021-05-27 2024-01-30 셀진 코포레이션 조합 요법을 사용하는 다발성 골수종의 치료 방법
US20230142647A1 (en) * 2021-07-12 2023-05-11 Quteba Ebrahem Method of treating cancer or a blood disorder
US20250032483A1 (en) * 2021-12-03 2025-01-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating pain
CN116496246A (zh) * 2022-01-18 2023-07-28 中国药科大学 异吲哚啉类化合物、制备方法、药物组合物和应用
CN117045800A (zh) * 2022-05-06 2023-11-14 上海科技大学 mTOR抑制剂增强靶向蛋白降解药物功效的应用
CN119015299B (zh) * 2024-08-21 2026-06-02 中国医学科学院肿瘤医院 西奈芬净在治疗癌症中的应用
WO2026064898A1 (en) * 2024-09-24 2026-04-02 Chun Jiang Combination therapies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX2017001656A (es) 2014-08-08 2017-07-24 Pharmacyclics Llc Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
US20170232030A1 (en) 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
EP4201399A3 (en) * 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
DK3908281T3 (da) * 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom

Similar Documents

Publication Publication Date Title
US20230190760A1 (en) Advantageous therapies for disorders mediated by ikaros or aiolos
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
JP2022546471A5 (cg-RX-API-DMAC7.html)
FI3908281T3 (fi) Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
JP2023515817A (ja) ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ
KR20180113976A (ko) 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
US20150005262A1 (en) Hypoxia activated prodrugs and mtor inhibitors for treating cancer
JP2024501471A5 (cg-RX-API-DMAC7.html)
JP2022552880A (ja) 置換4-アミノイソインドリン-1,3-ジオン化合物および組合せ使用のための第2の活性剤
CN101511357A (zh) 治疗和预防眼部疾病的方法
JP2018530578A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
CN107406413A (zh) C21H22Cl2N4O2的晶型
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
JP2022535893A5 (cg-RX-API-DMAC7.html)
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
JP2018525411A (ja) 多発性骨髄腫を治療するためのbtk阻害剤の組み合わせ
BR112018074381B1 (pt) [8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il) metanonas, seu uso e seus métodos de preparação, composição e combinação farmacêutica, intermediários e seu uso
US9951041B2 (en) Crystalline C21H22Cl2N4O2 malonate
EP0528749B1 (en) Indole derivatives and their use
WO2018213770A1 (en) Therapeutic methods
CN121969357A (zh) Mrtx1133药物组合物
JP2018515507A5 (cg-RX-API-DMAC7.html)
RU2006126828A (ru) Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
AU2021401681A1 (en) Dosing of fedratinib